Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 212 clinical trials
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2)

in combination with trastuzumab and pertuzumab as maintenance treatment of patients with HER2-positive advanced breast cancer whose tumor harbors a PIK3CA mutation following induction therapy with a

  • 0 views
  • 30 May, 2022
  • 16 locations
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

. Finally a new, dose reduced induction therapy in combination with Imatinib will be evaluated in Ph/BCR-ABL positive ALL.

cytarabine
vp-16
pegaspargase
methotrexate
b-cell acute lymphoblastic leukemia
  • 193 views
  • 24 Jul, 2022
  • 1 location
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

, temozolomide and rituximab as induction therapy, followed by temozolomide as maintenance treatment; the aim is to evaluate the efficacy of this combination of treatment.

maintenance treatment
methotrexate
rituximab
whole-brain radiotherapy
cancer
  • 0 views
  • 13 May, 2022
  • 35 locations
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

; cytarabine as induction therapy. (Randomisation 1 (R1) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.)

cytarabine
mitoxantrone
daunorubicin
ejection fraction
idarubicin
  • 0 views
  • 26 Jan, 2022
  • 69 locations
A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (CAALL-F01)

asparaginase administration is proposed during induction therapy: 2 infusions of 2500 IU/m2/day (D12 and D26) will be administered. All patients will receive 2500 IU/m2 per dose during consolidation and

asparaginase
lymphoid leukemia
pegaspargase
induction therapy
  • 0 views
  • 26 Jan, 2022
  • 28 locations
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and

melphalan
isotretinoin
cyclophosphamide
high-risk neuroblastoma
doxorubicin
  • 310 views
  • 26 Jan, 2021
  • 126 locations
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

> A phase III, multi-centre, randomised controlled trial to compare standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with the novel triplet ixazomib, lenalidomide and

dexamethasone
lenalidomide
  • 0 views
  • 23 Jun, 2021
  • 109 locations
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may …

colony-stimulating factors
mdx-ctla-4
diabetes
interferon
advanced melanoma
  • 162 views
  • 17 Sep, 2022
  • 416 locations
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, …

tumor necrosis factor
infliximab
methotrexate
immunosuppressive agents
tumour necrosis
  • 207 views
  • 20 Sep, 2022
  • 323 locations
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, …

monoclonal protein
chemotherapy regimen
bortezomib
hypertension
prednisone
  • 21 views
  • 09 Dec, 2021
  • 378 locations